• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Arthrex looks to Supreme Court in patent spat with KFx Medical

Arthrex looks to Supreme Court in patent spat with KFx Medical

September 21, 2015 By Fink Densford

Arthrex, KFx Medical

Arthrex asked the U.S. Supreme Court to reverse a $29 million Federal Circuit Court patent decision from a case against rival KFx Medical, according to court filings submitted Sept. 4.

In the writ of certiorari, Arthrex said that the court’s decision to treat the “reason to combine” question in determining the obviousness of patent validity as a factual issue was “inexplicable,” according to court filings.

The “reason to combine” question is central to whether or not a patent would be obvious to highly trained developers in the field at the time of its conception, which in turn is essential to patent law, Arthrex claimed. The company claims the issue should be re-reviewed upon appeal, or de novo, not merely dismissed if found erroneous.

“The Federal Circuit’s approach, moreover, hobbles the judiciary in reviewing obviousness determinations,” Arthrex wrote. “The Federal Circuit purports to review the jury’s ultimate conclusion on obviousness de novo. But treating motivation to combine pre-existing art as a fact question effectively converts the ultimate question of obviousness into a fact question as well.”

In the petition, Arthrex also raised the issue of whether a jury should decide on cases of “obviousness,” and asserted that they should be treated like claim construction decisions and resolved by judges.

“The ‘unfortunate practice’ of having the jury decide issues related to obviousness does the opposite – the verdict is a black box that is ‘essentially immune to review by the trail court,'” Arthrex wrote.

The patent-spat involves KFx’s patent of a knotless bridged soft-tissue suture system that uses multiple bone anchors and sutures that can be tightened after being placed with no knots.

Arthrex produces PushLock and SwivelLock knotless anchors, which are used in its SutureBridge and SpeedBridge surgical procedures to attach soft tissue to bone.

KFx sued Arthrex in August 2011, alleging infringement of its patents by Arthrex’s SutureBridge and SpeedBridge devices for rotator cuff repair and Achilles tendon repair.

In October 2013 a jury found for KFx, awarding $29 million in damages. Judge Dana Sabraw of the U.S. District Court for Southern California later denied an Arthrex motion for a new trial and tacked on another $1.9 million in damages and prejudgment interest of 7%.

The U.S. Court of Appeals for the Federal Circuit in January denied Arthrex’s appeal, prompting the Naples, Fla.-based company to ask the appeals bench for a full, en banc review.

In April, the Federal Circuit denied that bid and issued an April 17 mandate enforcing the ruling.

Filed Under: Legal News, Orthopedics, Patent Infringement Tagged With: Arthrex Inc., KFx Medical

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy